Hu Panwei

Dr. Hu Panwei


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

13 June 2025 in Nutrition & Metabolism
Verified
Journal Article
Open access
PDF file
LLLi Li
Li Li
JMJuanjuan Ma
Juanjuan Ma
NSNingyu Sun
Ningyu Sun
HPHu Panwei
Hu Panwei
YLYi Lin
Yi Lin
QZQinhua Zhang
Qinhua Zhang
Female reproductive diseases—including endometriosis (EMs), uterine fibroids (UFs), polycystic ovary syndrome (PCOS), gestational diabetes mellitus (GDM), eclampsia, ectopic pregnancy (EP), infertility, miscarriage, and ovarian aging—pose significant global health challenges. Metabolic syndrome (MetS) is characterized by a series of metabolic irregularities and has been linked to distinct plasma metabolomic profiles. Investigating the etiological connections among MetS, plasma metabolites, and female reproductive diseases is essential for devising effective prevention and treatment strategies. This study sought to evaluate the causal relationships among MetS, plasma metabolites, and female reproductive diseases using a two-step Mendelian randomization (MR) methodology. Initially, MR investigations were conducted to determine the causative impact of MetS on nine female reproductive diseases utilizing genome-wide association study (GWAS) data procured from European-descent populations. Statistically significant associations were identified for five diseases: UF, PCOS, GDM, eclampsia, and miscarriage. One hypothesis is that plasma metabolites may contribute to these associations. Subsequently, comprehensive MR analyses were performed using GWAS data on 233 plasma metabolites to examine causal relationships between these MetS-associated reproductive conditions and eight distinct classes of plasma metabolites. Sensitivity analyses, replication studies, and colocalization assessments were performed to validate the reliability of the outcomes. MetS was identified as a causal factor for increased risks of UF, PCOS, GDM, eclampsia, and miscarriage. Further MR analyses revealed that specific plasma metabolites might causally affect the risk of female reproductive diseases: Eclampsia: Protective associations were observed with lipid molecules in large and very large high-density lipoprotein (HDL) particles, including cholesterol esters and total cholesterol. Conversely, triglycerides in large HDL particles and indicators related to small HDL particles were linked to increased risk. PCOS: Risk factors included elevated levels of triglycerides in HDL particles, various very low-density lipoprotein metabolites, acetone, 3-hydroxybutyrate, and conjugated linoleic acid. GDM: Increased glucose levels were associated with increased GDM risk. This investigation established that MetS causally elevates the risk of certain female reproductive diseases and identified plasma metabolites that influence these conditions. These findings enhance the understanding of the etiological pathways involved in MetS and reproductive disorders, highlighting plasma metabolites as potential biomarkers or therapeutic targets.

30 June 2025 in Drug Discoveries & Therapeutics
Verified
Journal Article
Open access
PDF file
QLQian Liu
Qian Liu
YWYang Wang
Yang Wang
HPHu Panwei
Hu Panwei
PHPeizhi He
Peizhi He
Biologics are essential for managing immune-related inflammatory diseases during pregnancy to prevent disease progression and adverse pregnancy outcomes. However, data on the safety of biologics in a broader population are limited. This study aims to evaluate abortion-related adverse events (AEs) associated with adalimumab, etanercept, ustekinumab, and dupilumab, using data from the FDA Adverse Event Reporting System (FAERS) database. A disproportionality analysis was performed using the Reporting Odds Ratio (ROR) and Bayesian Confidence Propagation Neural Network (BCPNN) to identify signals of abortion-related AEs. The time-to-onset profiles were assessed by analyzing the description and Weibull shape parameters (WSPs) for these events. Sensitivity analyses were also conducted, including drug–drug interaction studies, logistic regression, and a similar retrospective analysis using data from the Japanese Adverse Drug Event Report (JADER) database. Disproportionality analysis revealed specific signals for abortion-related AEs associated with adalimumab, etanercept, and ustekinumab. The drug–drug interaction analysis indicated that these biologics, particularly without methotrexate or prednisolone, increase the risk of abortion-related AEs. Logistic regression identified several factors influencing outcomes. The time-to-onset analysis revealed that dupilumab had an earlier onset of 62.5 days, while etanercept had a later onset at 184 days. WSPs analysis revealed that signals for adalimumab, ustekinumab, and dupilumab exhibited early failure-type features, indicating a decreasing risk of abortion-related AEs over time. In conclusion, adalimumab, etanercept, and ustekinumab are associated with an increased risk of abortion-related adverse pregnancy outcomes, though the signals remain relatively weak. Further large-scale studies are needed to provide more definitive evidence.